Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

7.430 +0.330 (+4.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Looking Into Prothena Corp's Return On Capital Employed
Via Benzinga
Recap: Prothena Corp Q1 Earnings
Via Benzinga
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Prothena Corp Earnings Preview
Via Benzinga
Another Sucess In Alzheimer’s Disease
Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments? 
Via Talk Markets
Where Prothena Corp Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Prothena Corp
Via Benzinga
Earnings Outlook For Prothena Corp
Via Benzinga
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
Via Benzinga
Prothena to Report First Quarter 2023 Financial Results on May 4
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in 2023 Bank of America Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial
From Walgreens
Via Business Wire
Analyst Expectations for Prothena Corp's Future
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
Via Benzinga
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in Stifel 2023 Virtual CNS Days
From Prothena Corporation plc
Via Business Wire
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... 
Via FinancialNewsMedia
Exposures COVID-19
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
From Prothena Corporation plc
Via Business Wire
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Prothena Corporation plc
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Prothena Corporation plc
Via Business Wire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. 
Via Talk Markets
How To Weather These Choppy Markets
Until we get an absolute bottom in the markets, the best way to avoid experiencing a devastating permanent loss of capital is to keep away from stocks with deteriorating fundamentals and heavy insider... 
Via Talk Markets
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.